Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01287182

Enrollment

100

Registered

2011-02-01

Start date

2011-05-31

Completion date

2011-12-31

Last updated

2013-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Keywords

Asymptomatic Myocardial Ischemic patients

Brief summary

This is a trial of Ateronon in Patients with Coronary Disease to Evaluate its Effectiveness in Assessing the Risk Factors of Atherosclerosis.

Interventions

DRUGAteronon

Ateronon daily for 3 months

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

35 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Men and Women with demonstrated Coronary Disease * AtheroAbzyme positive during screening process * Elevated Total Cholesterol * Willingness to take study nutritional supplement once a day for 3 months

Exclusion criteria

* Women who are pregnant, nursing or intend pregnancy during the period of treatment * Known milk, soy or whey allergy

Design outcomes

Primary

Measure	Time frame
to evaluate the effectiveness of Ateronon in inhibiting atherogenic lipid oxidation in patients with demonstrated coronary disease	Baseline and 3 months

Secondary

Measure	Time frame
to evaluate the potential effectiveness of Ateronon in lowering pulse rate as well systolic and diastolic blood pressure in patients with demonstrated coronary disease	Baseline and 3 months

Countries

Lebanon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026